Important pharmacy news and late-breaking industry information updated daily.

FDA approved on Tuesday romosozumab-aqqg (Evenity—Amgen) for the treatment of osteoporosis in postmenopausal women at high risk of fracture. These women have a history of osteoporotic fracture or multiple risk factors for fracture, or they have failed or are intolerant of other osteoporosis treatments.

FDA is transitioning certain biological products currently regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act)—which governs the generic pathway for conventional drugs (a.k.a. small molecules)—to be licensed as biologics under the Public Health Service Act (PHS Act). This includes insulin, a biologic drug, according to an FDA statement published on April 2, 2019.

According to new research published April 8 in Pediatrics, telemedicine visits resulted in 52% of antibiotic prescriptions for children with acute respiratory infections. Less frequent prescribing was observed in urgent care and in-person visits with a physician, at 42% and 31%, respectively.

FDA on Monday issued a safety communication about the risks of using pre-owned test strips or test strips not authorized for sale in the United States, warning that they may potentially cause infection or lead to inaccurate test results.

Amazon plans to use its artificial intelligence assistant Alexa to track consumers' prescriptions and relay personal health information, reporting that the device can now transfer sensitive, personal health information using software that meets health privacy requirements under federal law.

For the first time since FDA discovered a nitrosamine impurity in angiotensin II receptor blockers (ARBs) last summer, the agency said Thursday it has identified 40 ARBs that do not contain any known nitrosamine impurities. This number is expected to increase.

FDA officials reported Wednesday that some people who use e-cigarettes, particularly youth and young adults, have experienced seizures following their use.

Express Scripts said Wednesday it will immediately begin offering employers, labor unions, and other clients the option to cap at $25 a month the copayments and other out-of-pocket costs that diabetics must pay to fill their insulin prescriptions.

Treatment of hypertension to systolic blood pressure (SBP) levels of less than 120 mm Hg did not result in a lower incidence of dementia, but did significantly reduce the risk of mild cognitive impairment compared with less-intensive BP control to SBP levels of less than 140 mm Hg, according to new data from the SPRINT MIND trial published in JAMA.